Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid

a technology of senescent cells and flavonoid, which is applied in the field of treatment and prophylaxis of senescent cellassociated diseases and disorders, can solve the problems that the presence of senescent cells may have deleterious effects on millions of patients worldwid

Inactive Publication Date: 2017-08-03
MAYO FOUND FOR MEDICAL EDUCATION & RES
View PDF3 Cites 34 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0030]In another embodiment, a method is provided for treating or reducing the likelihood of occurrence of atherosclerosis in a subject who has atherosclerosis or who has at least one predisposing factor for developing atherosclerosis, comprising administering to the subject a senolytic combination comprising (a) a first agent that alters either one or both of a cell survival signaling pathway and an inflammatory pathway in the senescent cell, and (b) a second agent that alters either one or both of a cell survival signaling pathway and an inflammatory pathway in the senescent cell, thereby promoting death of the senescent cell, wherein the combination is administered once every 0.5-12 months, and wherein the first and second agents are different.

Problems solved by technology

Given that senescent cells have been causally implicated in certain aspects of age-related decline in health and may contribute to certain diseases, and are also induced as a result of necessary life-preserving chemotherapeutic and radiation treatments, the presence of senescent cells may have deleterious effects to millions of patients worldwide.
However, identifying and developing treatments of such diseases and conditions by selective elimination of senescent cells has been an arduous undertaking.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
  • Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
  • Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid

Examples

Experimental program
Comparison scheme
Effect test

example 1

Identification of Senescence Associated Pathways

[0264]Proteomic analyses by nano LC MS / MS were performed on lysates on human abdominal subcutaneous preadipocytes that were senescent or non-senescent. Preadipocytes, one of the most abundant cell types in humans susceptible to senescence, were extracted from fat tissues of nine different healthy kidney transplant donors by collagenase digestion. Prior consent from the donors was obtained. Senescence was induced by 10 Gy radiation or by serial subculturing. Bioinformatics methods were used to identify pathways that were susceptible to existing drugs and that could mediate cell death.

[0265]Senescence-associated β-galactosidase (SA-β gal) activity was used to assess the percentage of senescent cells present in the irradiated cell cultures. To be considered a senescent culture, 75% or more of the cells needed to demonstrate SA-β gal activity. Both whole cell lysates and cellular supernatants were collected. Proteins were separated on 1D S...

example 2

Selective Killing of Senescent Fibroblasts

[0268]Senescence of human primary lung fibroblasts (IMR90) (IMR-90 (ATCC® CCL-186™, Mannassas, Va.) was induced by irradiation. IMR90 cells in culture were subjected to 10 Gy radiation (Day −7). Four days after irradiation (Day −3), the culture media was changed. Three days after the media change (Day 0), the cells were exposed to media containing quercetin. Non-irradiated IMR90 cells were included as controls. Non-irradiated and irradiated IMR90 cells were exposed to quercetin at concentrations of 5, 10, 15, and 45 μM. Percent survival was determined four days after exposure to the drugs (Day 4). The number of viable cells was determined by using ATPLITE (Perkin-Elmer, Waltham, Mass.). The results are presented in FIG. 3.

[0269]In a separate experiment, IMR90 cells were irradiated as described above to induce senescence. Approximately 20 days after irradiation, the senescent cells and proliferating IMR90 cells were exposed to enzastaurin at ...

example 3

Selective Killing of Senescent Endothelial Cells

[0271]Human umbilical endothelial cells (HUVEC) (Lonza Group, Basel, Switzerland) were induced to senescence by exposure to 10 Gy radiation. Twenty days after irradiation, markers of cellular senescence (SA-β Gal) and growth arrest, determined by incorporation of BRdU, were evident. Non-senescent HUVEC cells used as control were plated at low density in culture media so that the cells were proliferating when exposed to the test drug. Senescent HUVEC cells and non-senescent, proliferating HUVEC cells were treated for 48 hours with quercetin, dasatinib, and enzastaurin as follows: (1) quercetin alone at 3.75, 7.5 and 15 μM; (2) dasatinib alone at 25, 50, 100, and 200 nM; (3) enzastaurin alone at concentrations of 0.25 μM, 0.5 μM, 1 μM, and 2 μM; (4) dasatinib at 100 nM plus quercetin at 7.5 μM; (5) with dasatinib at 50 nM plus quercetin at 7.5 μM; (6) dasatinib at 100 nM plus enzastaurin at 1.0 μM; (7) dasatinib at 100 nM plus enzastauri...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
Login to view more

Abstract

Provided herein are methods and uses for treatment or prophylaxis of a senescent cell associated disease or disorder by administering a senolytic combination comprising dasatinib and quercetin or an analog thereof to a subject in need thereof. In certain embodiments, the senescent cell associated disease or disorder is a cardiovascular disease or disorder, inflammatory disease or disorder, a pulmonary disease or disorder, a neurological disease or disorder, or a metabolic disease or disorder.

Description

STATEMENT OF GOVERNMENT INTEREST[0001]This invention was made with government support under Grant No. AG41122 and AG046061 awarded by the National Institutes of Health. The government has certain rights in this invention.BACKGROUND[0002]Technical Field[0003]The disclosure herein relates generally to methods for treatment and prophylaxis of senescent cell-associated diseases and disorders.[0004]Description of the Related Art[0005]Senescent cells accumulate in tissues and organs of individuals as they age and are found at sites of age-related pathologies. Senescent cells are believed important to inhibiting proliferation of dysfunctional or damaged cells and particularly to constraining development of malignancy (see, e.g., Campisi, Curr. Opin. Genet. Dev. 21:107-12 (2011); Campisi, Trends Cell Biol. 11:S27-31 (2001); Prieur et al., Curr. Opin. Cell Biol. 20:150-55 (2008)); nevertheless, the presence of senescent cells in an individual may contribute to aging and aging-related dysfunc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/506A61K31/352
CPCA61K31/352A61K31/506A61K45/06A61K31/353A61K31/665A61K31/7048A61K2300/00
Inventor KIRKLAND, JAMES L.TCHKONIA, TAMARZHU, YIPALMER, ALLYSON K.LEBRASSEUR, NATHAN K.MILLER, JORDAN D.
Owner MAYO FOUND FOR MEDICAL EDUCATION & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap